News
NIH inventors have developed the first pharmacologic option for developmental stuttering, which is currently only managed by speech therapy, but addresses a $3 billion underserved global market. This technology uses small-molecule iron chelators – drugs that bind and remove excess iron – for the
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Meet with NIH Technology Transfer experts at the BioHealth Capital Region Forum to discuss how companies, entrepreneurs, and other buy-side stakeholders can partner with the NIH to bolster their pipeline. We can discuss partnership models beyond academic/basic research and SBIRs, success stories and
NIH’s Steven Ferguson and Michael Salgaller have co-written a chapter in the recently released book, Science for a Better Tomorrow. Their chapter, The U.S. National Institutes of Health: Inspiring Innovation in Biomedicine and Health, is an insightful read for anyone who is looking to better